Transforming mental health care with psilocybin.

Declaration
APEX is a patient-driven pharmaceutical company advancing psilocybin-based therapies to treat the most critical unmet needs in mental health.

Mission
To develop, clinically evaluate, and commercialize APEX’s dual drug assets that address depression and PTSD, primarily focusing on Veteran populations.

Vision
To redefine the standard of care in mental health by enabling physicians worldwide to access and prescribe APEX products with confidence.

Why Now?
Today’s standard antidepressant therapies are only 40–60% effective with nearly half of patients report unwanted side effects.

The need is urgent, the time is now.

Market Opportunity

  • 1
  • 2
  • 3

  • 322 million

    People globally deal with depression

  • 280 million

    People globally suffer from PTSD

  • $19.5 Billion USD

    Forecasted size of the anxiety disorder and depression treatment markets by 2028